What is Adecto Pharmaceuticals?
Adecto Pharmaceuticals is a pre-clinical stage therapeutic company dedicated to pioneering targeted treatments for aggressive ADAM8-positive cancers. Leveraging over three decades of dedicated research, the company's mission is to develop novel therapies capable of halting both primary tumor growth and metastatic spread. Their strategy includes the development of a companion diagnostic to precisely identify patient populations most likely to benefit from their treatments. The initial therapeutic focus is on breast cancer, with strategic plans for future expansion into other oncology indications. An estimated 2 million patients globally stand to benefit from Adecto's innovative product pipeline.
How much funding has Adecto Pharmaceuticals raised?
Adecto Pharmaceuticals has raised a total of $48K across 1 funding round:
Debt
$48K
Debt (2021): $48K with participation from PPP
What's next for Adecto Pharmaceuticals?
With the recent influx of significant expansion capital, Adecto Pharmaceuticals is poised for accelerated development and strategic growth. This funding is expected to fuel the progression of their pre-clinical pipeline, particularly their targeted treatments for ADAM8-positive cancers. The company's focus on developing a companion diagnostic alongside its therapeutics indicates a commitment to precision medicine, a key trend in modern oncology. The successful deployment of this investment will be critical in advancing their lead programs towards clinical trials and ultimately bringing their potentially life-saving therapies to patients, starting with breast cancer and expanding into other indications.
See full Adecto Pharmaceuticals company page
